FDA clears rectal cancer immunotherapy without surgery

The US Food and Drug Administration granted accelerated approval to dostarlimab-gxly for adult patients with mismatch repair-deficient (dMMR) locally advanced rectal cancer. The decision follows clinical data where 100 percent of an initial 41-patient cohort achieved complete clinical response, defined by magnetic resonance imaging and endoscopy, without receiving chemotherapy, radiation, or invasive surgical resections.

Standard oncological pathways for this disease historically involve pelvic radiation and total mesorectal excision. These interventions routinely leave people with permanent stomas, severe bowel dysfunction, or sexual and urinary nerve damage. Dostarlimab operates by binding to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2 ligands to enable endogenous T cells to target the tumor directly.

This pathway depends on reliable upfront diagnostics. A mismatch repair deficiency accounts for roughly 5 to 10 percent of rectal cancers, meaning accurate identification requires high-confidence genetic testing or automated immunohistochemistry interpretation. When pathology pipelines miss the biomarker, patients default to conventional, destructive chemoradiation.

If you or a family member face a colorectal diagnosis, request explicit genetic confirmation of MMR status and microsatellite instability before signing off on pelvic radiation plans.